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Copy number variation in bipolar disorder
EK Green1, E Rees2, JTR Walters2, K-G Smith3, L Forty2, D Grozeva4, JL Moran5, P Sklar6, S Ripke5,7, KD Chambert5, G Genovese5,
SA McCarroll5, I Jones2, L Jones3, MJ Owen2, MC O’Donovan2, N Craddock2 and G Kirov2
Large (4100 kb), rare (o1% in the population) copy number variants (CNVs) have been shown to confer risk for schizophrenia (SZ),
but the ﬁndings for bipolar disorder (BD) are less clear. In a new BD sample from the United Kingdom (n= 2591), we have examined
the occurrence of CNVs and compared this with previously reported samples of 6882 SZ and 8842 control subjects. When
combined with previous data, we ﬁnd evidence for a contribution to BD for three SZ-associated CNV loci: duplications at 1q21.1
(P= 0.022), deletions at 3q29 (P= 0.03) and duplications at 16p11.2 (P= 2.3 × 10− 4). The latter survives multiple-testing correction
for the number of recurrent large CNV loci in the genome. Genes in 20 regions (total of 55 genes) were enriched for rare exonic
CNVs among BD cases, but none of these survives correction for multiple testing. Finally, our data provide strong support for the
hypothesis of a lesser contribution of very large (4500 kb) CNVs in BD compared with SZ, most notably for deletions 41 Mb
(P= 9× 10− 4).
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INTRODUCTION
There is strong evidence for a substantial genetic contribution to
risk for both bipolar disorder (BD) and schizophrenia (SZ).1 Recent
studies have provided evidence that while some alleles confer a
speciﬁc susceptibility to either BD or SZ, others confer suscept-
ibility to both disorders.2 Large-scale genome-wide association
studies have identiﬁed common variants (minor allele frequency
40.01) that increase risk of both BD and SZ at CACNA1C, ANK3,
ITIH3-ITIH4, ZNF804A and NCAN.3–8 Polygenic risk score analyses
have also shown that large numbers of alleles that are yet to be
identiﬁed at genome-wide signiﬁcance are over-represented in SZ
cases and are also over-represented in cases of BD.9
Copy number variants (CNVs) are structural genomic variations
that are 41 kb in size and occur in the form of deletions,
duplications, insertions and inversions (reviewed in Malhotra and
Sebat10). Large, rare CNVs (4100 kb in size and present in o1%
of individuals) increase risk for SZ and other neurodevelopmental
disorders including autism spectrum disorders, intellectual dis-
ability, attention deﬁcit hyperactivity disorder, developmental
delay and epilepsy.10–14 In a recent study, we showed that 11 CNV
loci are signiﬁcantly associated with SZ and four more loci are
potentially implicated.15 Overall, 2.5% of individuals with SZ carry
at least one of these 15 CNVs, compared with 0.9% of controls.15
CNVs have been less well studied in BD; the evidence for their
involvement in typical forms of the disorder is less clear-cut than
in SZ.2 Studies in general have not found a signiﬁcant increase in
the rate of rare CNVs in individuals with BD compared with
controls.16–19 However, it has been reported that singleton dele-
tions over 100 kb in length are more frequent in BD cases,17,18 that
an increased rate of CNVs occurs in early-onset BD cases,20 that
the frequency of de novo CNVs are signiﬁcantly more frequent in
BD cases (with an onset below 18 years of age) than controls21
and that the rate of de novo CNVs in BD are intermediate between
SZ and controls.22 We have not observed such excesses in the
Wellcome Trust Case Control Consortium (WTCCC) BD CNV
analysis, and we did note that the overall rate of CNVs seen in
BD cases was less than that found in individuals with SZ16 and
signiﬁcantly lower than in a reference group with other non-
psychiatric disorders.23
In a recent review, Malhotra and Sebat10 reported the rate for
CNVs at speciﬁc loci that have received the strongest support for a
variety of disorders (intellectual disability, developmental delay,
autism spectrum disorder, SZ, and BD and recurrent depression)
by combining all available data. The CNV occurrence at each
locus was reported for BD and recurrent depression combined,
and suggested an increase of CNVs at four loci: deletions at 3q29
and 22q11.21, and duplications at 1q21.1 and 16p11.2. The inci-
dence of CNVs at these loci for just BD was not reported
separately.
In this study, we examined CNVs in a new United Kingdom BD
data set (n= 2591), the Bipolar Disorder Research Network sample
(www.BDRN.org). This sample is independent of the WTCCC data
set we previously reported.16,23 We performed three types of
analysis of rare CNVs (o1% of the population): (1) we compared
the rate of CNVs in BD vs controls at 15 loci that received support
for association with SZ, using all available large data sets.15,24 (2)
We examined each gene across the genome for exon-disrupting
CNVs in BD compared with controls, using a size cutoff of 10 kb.
(3) We compared the burden of very large CNVs (4500 kb in size)
in BD with that in a large SZ data set from the United Kingdom
(CLOZUK and CardiffCOGs, n= 6882) and with publicly available
data from control individuals typed on similar arrays (n= 8842).24
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MATERIALS AND METHODS
Bipolar disorder cases
The BD sample is a new collection called the Bipolar Disorder Research
Network sample (www.BDRN.org), recruited in collaboration with the
Stanley Center for Psychiatric Research at the Broad Institute of MIT and
Harvard. All participants were unrelated, white European, living in the
British Isles. The protocols and procedures were approved by the relevant
ethics review panels where patients were recruited. The individuals were
recruited if they suffered with a major mood disorder in which clinically
signiﬁcant episodes of elevated mood had occurred. Bipolar cases were
excluded if they had experienced mood or psychotic illness only as a result
of alcohol or substance dependence or medical illness or medication;
or were biologically related to another study participant. The following
methodology was used for assessment of bipolar cases: a semi-structured
lifetime ever psychiatric interview (Schedules for Clinical Assessment in
Neuropsychiatry),25 followed by clinical ratings and a best-estimate lifetime
diagnosis according to the Research Diagnostic Criteria.26 In cases where
there was doubt as to the best-estimate lifetime diagnosis, diagnostic and
clinical ratings were made by at least two members of the research team
blind to each other’s ratings.
The BD cases consisted of 2637 individuals of which 30.8% were male.
The mean age of recruitment was 46 years (s.d. = 12), with a mean age at
ﬁrst impairment due to BD of 28 years (s.d. = 11). There were 61% bipolar I
disorder/mania, 32% bipolar II disorder/hypomania and 7% schizoaffective
disorder, bipolar type.
Schizophrenia cases
For comparison of BD with SZ, we used two UK-based samples that we
previously described and analysed for CNVs.12,15,24 The CLOZUK SZ cases
(n=6558) consist of individuals taking the antipsychotic clozapine.
Subjects (71% male) were aged 18–90 years with a recorded diagnosis
of treatment-resistant SZ according to the clozapine registration forms
completed by their psychiatrists. The use of these anonymised samples for
genetic association studies was approved by the local Ethics Committee.
The CardiffCOGS (n= 571) is a sample of clinically diagnosed SZ patients
recruited from community, inpatient and voluntary sector mental health
services in the United Kingdom. Interview with the SCAN instrument25 and
case-note review was used to arrive at a best-estimate lifetime diagnosis
according to DSM-IV criteria.27
Controls
The control data sets comprised the same sample described in Rees et al.24
in a study of SZ, we did not include WTCCC1 controls used in Rees et al.,24
as they have been previously used in our WTCCC BD CNV analysis.16 The
remaining controls (before quality control (QC) ﬁltering) from Rees et al.24
were participants in a smoking cessation study from the United States
(n=1491), individuals from the United States who took part in a study of
melanoma (n= 3102, ~ 2/3 individuals were affected with melanoma),
individuals from Germany who were participants in a refractive error study
(KORA study) (n= 1869) and WTCCC2 controls (National Blood Donors
cohort: n=1392 and the 1958 British birth cohort: n=1521). These data
sets were chosen because they had been genotyped with Illumina (San
Diego, CA, USA) arrays that have a high probe overlap with the arrays used
to genotype the BD cases in the current study. Full details of these samples
are available in the Supplementary Material. A total of 93.5% of controls
were of European descent.
Genotyping and QC ﬁltering
Details of the arrays used for genotyping the data sets are available in the
Supplementary Material; Supplementary Table S1. The steps for genotyp-
ing and QC ﬁltering for the BD cases were performed as described in the
previously reported SZ sample.15 To ensure that the CNV calling was
comparable across the different arrays, only probes that were present on
all arrays were analysed, resulting in a total of 520 766 probes. In addition,
to avoid batch effects, raw intensity ﬁles from each BD, SZ and control data
set were analysed independently.
The Illumina GenomeStudio software (v2011.1) was used to process the
raw intensity data, generating Log R Ratios and B-allele frequencies. BD
samples were excluded if any of the following QC statistics constituted an
outlier within their source data set: Log R ratios s.d., B-allele frequency drift,
wave factor and total number of CNVs. Out of the 2637 BD samples with
array data, 46 were excluded due to (i) poor QC, (ii) duplicates or related
(piHat40.1) individuals of this or previous BD studies by identity by
descent and (iii) incorrect gender. The numbers and the ethnicities of these
subjects are listed in Supplementary Material; Supplementary Table S2. The
ﬁnal numbers after exclusions for QC and duplicates were 2591 BD cases,
6882 SZ cases and 8842 controls. These samples were used for the
comparisons between SZ and BD, and for the identiﬁcation of new loci,
whereas larger, publicly available data sets were used for the analysis of
the 15 SZ-associated loci.
CNVs went through QC steps described in more detail in the Supple-
mentary Methods. Brieﬂy, CNVs were included if their frequency was o1%
(applied using PLINK28). Subsequently, CNVs were further validated by
applying a median Z-score outlier method of validation.29 Different size
cutoffs were used for the different types of analysis, as detailed below.
Statistical analysis
The rates of CNVs at speciﬁc loci for BD and controls were compared using
Fisher’s exact test (two tailed). In order to determine genome-wide
signiﬁcance, we followed a previous practice by employing a Bonferroni
correction for multiple testing of recurrent CNVs that are ﬂanked by
segmental duplications.11,15,24,30 The resulting P-value threshold of
4.1 × 10− 4 is based on 120 genomic regions that are prone to recurrent
CNVs (P=0.05/120). When examining associations with CNVs at individual
genes, accounting for testing ~ 20 000 genes, we employed a gene-wide
association threshold of Po2.5 × 10− 6.
The burden analysis of very large, rare CNVs was performed with PLINK28
using 10 000 permutations. The analysis was stratiﬁed by CNV size
(500 kb–1Mb and 41 Mb), testing deletions and duplications separately.
To identify novel loci a gene-based approach was used.24 Each gene in the
genome was examined for exon-disrupting CNVs using hg19 reference
sequence gene coordinates (UCSC genome browser and includes non-
coding RNAs). Deletions and duplications 410 kb were counted and
analysed separately, and signiﬁcance levels were generated using Fisher’s
exact test (two tailed) comparing the incidence in BD cases against
controls. Potential regions were excluded if manual inspection of Z-scores,
Log R ratios and B-allele frequency traces suggested that they were
unreliable.24,29
Power calculations were performed using the online open source
genetic power calculator (http://pngu.mgh.harvard.edu/ ~ purcell/gpc/).31
Frequencies and odd ratios for BD were taken from the review by Malhotra
and Sebat.10
RESULTS
Previously implicated SZ loci
We examined the rates of CNVs in BD cases and control groups at
15 loci previously implicated in SZ.15 The CNV rates were based on
the following data sets: (i) BDRN cases in this current study, (ii)
data from a meta-analysis by Malhotra and Sebat10 for BD cases
(after excluding those with major depression), (iii) BD cases from
the study by Bergen et al.,18 in a Swedish population and (iv)
samples used in our previous CNV study16 using the BD cases from
the WTCCC1 for loci that were not included in the Malhotra and
Sebat10 study. In some instances, one or more of these four
sources did not provide data for a particular CNV locus. A full
description of which sources contributed to each of the 15 CNVs
analysed is provided in the Supplementary Material; Supplemen-
tary Table S3. The CNV occurrence in controls are taken from Rees
et al.,15 which reports the data from large combined control data
sets ranging from 27 045 to 81 821 samples in total.
The rates of CNVs in all reported large BD data sets and control
groups at the 15 loci are presented in Table 1. For 3 of the 15
CNVs, we noted nominally signiﬁcantly higher rates in BD cases
than in controls (without correction for multiple testing). The
strongest evidence for association was obtained for duplications
at 16p11.2, which were increased in BD cases (0.13%) compared
with controls (0.03%) with a combined P-value of 2.3 × 10− 4,
surpassing our genome-wide signiﬁcance threshold for this type
of CNV (see Methods) and strengthening the evidence from
previous studies. Supplementary Figures S1 and S2 indicate the
positions of the duplications, Log R ratios and B-allele frequency
traces using Illumina GenomeStudio in the three BD samples
CNVs in bipolar disorder
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across 16p11.2. The other nominally signiﬁcant loci were dupli-
cations at 1q21.1 and deletions at 3q29 (P-values, 0.022 and 0.03,
respectively), which do not survive any multiple-testing correction.
Analysis of novel CNV loci
Genes across the genome were examined for CNVs that disrupted
exons in the BD BDRN sample set (n= 2591) and control samples
(n= 8842), excluding the 15 previously implicated SZ loci reported
in Table 1. A total of 55 genes mapping to 20 distinct genomic
regions were enriched among our BD cases with nominal levels of
signiﬁcance (two-sided Fisher’s exact test, P-valueo0.05)
(Supplementary Table S4), but no gene reached the genome-
wide association threshold for the 20 000 genes examined
(Po2.5 × 10− 6). Within our data set, the strongest evidence for
association was for duplications at ATF7IP2 (encoding activating
transcription factor 7—interacting protein 2) located at 16p13.2–
p13.13, which was found in eight BD cases (0.31%) and in four
controls (0.045%, two-sided Fisher’s exact test, P= 1.4 × 10− 3). The
gene, GRIN2A encoding glutamate receptor, ionotropic, N-methyl-
D-aspartate, subunit 2A, lies downstream of ATF7IP2. Its ﬁrst exon
is disrupted in seven BD cases and ﬁve controls (0.27% BD vs
0.057% controls, two-sided Fisher’s exact test, P= 8.1 × 10− 3).
Supplementary Figure S3 indicates the positions of the duplica-
tions in all samples across ATF7IP2 and GRIN2A.
In addition, there is evidence of association for duplications at
the gene CGNL1 (cingulin-like 1) at 15q21.3, intersected in 13 BD
cases (0.50%) and 19 controls (0.21%), two-sided Fisher’s exact
test, P= 0.021. A signiﬁcant excess of duplications at this gene
have been previously observed in SZ.24 Supplementary Figure S4
indicates the positions of the duplications in the cases and
controls across CGNL1.
CNV burden analysis
We compared the rate of CNVs in BD with those in SZ cases and in
controls. The burden analyses were performed only on the BD, SZ
and control data sets where we had access to raw data and that
were genotyped with Illumina arrays (BD: n= 2591; SZ: n= 6882;
controls: n= 8842), as described in the Materials and methods
section. As CNV burden analysis is highly susceptible to technical
bias, we limited it to the largest class of CNVs, those 4500 kb,
which should be called reliably on all arrays used in different data
sets. BD cases were not signiﬁcantly different from controls in any
comparison (Table 2). SZ cases had more deletions 41 Mb
compared with BD cases (two sided, P= 9× 10− 4). Duplications in
the size range of 500 kb–1 Mb were also more common in SZ
compared with BD cases (two sided, P= 0.045). As this excess
could be due to the already implicated 15 SZ CNV loci (listed in
Table 1), the analysis was repeated after removing CNVs in these
loci. Neither of the comparisons remained even nominally signi-
ﬁcant, suggesting that a large part (but not all) of the excess in SZ
is due to CNVs at those known loci: (deletions 41 Mb, SZ 0.87%,
BD 0.54%, P= 0.12; duplications, 500–1 Mb, SZ 5.1%, BD 4.3%,
P= 0.12).
Table 1. Comparison of copy number variations (CNVs) in BD (BDRN data set and previously reported data for BD10,16,18), and the combined control
data set15 at 15 SZ-CNV-implicated loci
CNV frequency, % (n/N)
Locus Position Current BDRN BD study BD cases combined (total) Controls (total) OR (95% CI) P-value
1q21.1 del chr1:146 57–147 39 0.039% (1/2591) 0.033% (3/8968) 0.021% (17/81 821) 1.61 (0.47–5.50) 0.44
1q21.1 dup chr1:146 57–147 39 0.039% (1/2591) 0.099% (8/8084) 0.037% (24/64 046) 2.64 (1.19–5.88) 0.022
NRXN1 del chr2:5015–5126 0% (0/2591) 0% (0/4288) 0.020% (10/51 161) NA 1
3q29 del chr3:195 73–197 34 0% (0/2591) 0.025% (2/8084) 0.0014% (1/69 965) 17.31 (1.57–190.97) 0.03
WBS dup chr7:7274–7414 0% (0/2591) 0% (0/7250) 0.0058% (2/34 455) NA 1
VIPR2 dup chr7:158 82–158 94 0% (0/2591) 0.043% (2/8084) 0.069% (17/24 812) 0.36 (0.08–1.56) 0.19
15q11.2 del chr15:2280–2309 0.27% (7/2591) 0.17% (15/8966) 0.28% (227/81 802) 0.60 (0.36–1.02) 0.052
AS/PWS dup chr15:2482–2843 0% (0/2591) 0% (0/8084) 0.0063% (3/47 686) NA 1
15q13.3 del chr15:3113–3248 0% (0/2591) 0.043% (2/8084) 0.019% (15/80 422) 1.32 (0.30–5.80) 0.66
16p13.11 dup chr16:1551–1630 0.23% (6/2591) 0.11% (9/8084) 0.13% (93/69 289) 0.83 (0.42–1.64) 0.75
16p11.2 distal del chr16:2882–2905 0% (0/2591) 0% (0/4288) 0.018% (5/27 045) NA 1
16p11.2 dup chr16:2964–3020 0.12% (3/2591) 0.13% (12/9129) 0.030% (19/63 068) 4.37 (2.12–9.00) 2.3 × 10− 4
17p12 del chr17:1416–1543 0.039% (1/2591) 0.049% (4/8132) 0.026% (17/65 402) 1.89 (0.64–5.63) 0.28
17q12 del chr17:3481–3620 0% (0/2591) 0% (0/7250) 0.0054% (4/74 447) NA 1
22q11.2 del chr22:1902–2026 0% (0/2591) 0.012% (1/8084) 0% (0/77 055) NA 0.095
Abbreviations: BD, bipolar disorder; CI, conﬁdence interval; Del, deletions; Dup, duplications; NA, not applicable; OR, odds ratio. Positions are in Mb for UCSC
Build hg19.
Table 2. Burden analysis of large CNVs comparing SZ vs BD cases and BD cases vs controls (Con)
Size range CNV type BD SZ Con P-value, SZ v BD (% excess) P-value, BD v Con (% excess)
CNV freq (n CNV) CNV freq (n CNV) CNV freq (n CNV)
500 kb–1Mb Del 1.1% (29) 1.3% (90) 1.2% (102) 0.48 0.92
Dup 4.4% (114) 5.5% (377) 4.5% (401) 0.045 0.79
41Mb Del 0.62% (16) 1.5% (105) 0.61% (54) 9 × 10− 4 1
Dup 2.5% (65) 2.6% (180) 1.9% (168) 0.77 0.061
Abbreviations: CNV, copy number variations; BD, bipolar disorder; Del, deletions; Dup, duplications; SZ, schizophrenia. CNVs are stratiﬁed by type (deletions
and duplications) and size (500 kb–1Mb and 41Mb).
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DISCUSSION
It is well documented that speciﬁc CNVs contribute to the
susceptibility of SZ, however, the involvement of CNVs in BD is less
compelling. In a new independent BD sample, we have studied
rare, large CNVs and analysed their frequencies in this sample and
in previously reported BD, control and SZ data sets.10,15,16,18,24 The
incidence of CNVs in this new BD data set had not been previously
reported, although a large proportion of the sample has been
used for genome-wide association studies.3 The SZ, BD and
control samples were genotyped on a variety of Illumina arrays,
but only probes present on all arrays were analysed (n= 520 766).
In addition, for all data sets (SZ, BD and controls) the methodology
used was identical for CNV calling and statistical analysis.
Combining the BDRN BD data with recently reported CNV
analyses10,15,16,18,24 provided support for three of the 15 previously
implicated CNVs in SZ. Two of the loci, 1q21.1 duplication and
3q29 deletion were nominally signiﬁcant with a two-sided P-value
of 0.022 and 0.03, respectively, and these results do not survive
correction for multiple testing. The strongest evidence was for
duplications at 16p11.2 (two-sided P-value = 2.3 × 10− 4), which
survives correction for the number of potential recurrent CNV loci
in the genome (P-valueo4.2 × 10− 4) and is the most signiﬁcant
BD-associated CNV to date. The locus was implicated in BD
before10,32 (P= 8× 10− 4 for BD and major depression combined,10
P= 0.017 for BD32), but the current study raises the statistical
support to above a level that is regarded as genome-wide
signiﬁcant for this type of CNV locus. Additional phenotypic details
for the three carriers of 16p11.2 duplication are available in
Supplementary Information. All three individuals had a DSM-IV
rating of bipolar I disorder, and had episodes of depression as
well. There was nothing unusual in their recorded presentations
and at least two of them appeared to have no cognitive deﬁcits,
attaining O- or A-levels at school. The locus 16p11.2 has been also
previously implicated in neuropsychiatric disorders via a genome-
wide association study of mixed SZ and BD (psychosis)
phenotypes, which revealed a novel variant at 16p11.2 showing
genome-wide association for rs4583255 (P-value 6.6 × 10− 11, odds
ratio = 1.08) located in the 593-kb CNV duplication region33 within
the gene TAOK2. A signiﬁcant excess of a combination of micro-
deletions and duplications at 16p11.2 has also been reported in
major depressive disorder in a German sample.34
Our BD discovery sample consists of 2591 cases and 8842
controls, and has a power of 74 and 80% with an α of 0.05 to
detect associations with duplications at 1q21.1 and 16p11.2,
respectively. However, for the associations with the 15 SZ loci we
used all available data sets, increasing the numbers of BD cases to
~ 4000–9000 and the numbers of controls to those that provided
the deﬁnitive ﬁndings in SZ. Although the BD case numbers are
still smaller than for SZ, it is clear (Table 1) that for some of the loci
the frequencies in BD are very similar to those of controls,
suggesting that this is not a power problem but more likely a
genuine difference between SZ and BD.
We provide a list of the top hits for duplications and deletions at
55 genes that are more frequently affected in BD cases compared
with controls (Supplementary Table S4). The signiﬁcance for any of
these genes does not survive a Bonferroni correction for multiple
testing of 20 000 genes separately for deletions and duplications
(Po2.5 × 10− 6). The strongest evidence for association was
for duplications at ATF7IP2. GRIN2A, a glutamate receptor, lies
downstream of ATF7IP2, and although less signiﬁcantly associated
with BD, functionally it is the better candidate, as glutamate
signalling pathways are thought to be involved in genetic
predisposition to BD.35 In addition, GRIN2A is associated with SZ,
meeting genome-wide signiﬁcance.36 At the gene CGNL1 (cingu-
lin-like 1), there is overlap with our current BD data and SZ. Here,
we report an excess of duplications in BD cases compared with
controls in this gene, for which we also note an excess of
duplications in SZ cases compared with controls.24 However, we
note that the control samples used in the current BD study are not
independent of those used in the previous SZ study. Replication in
independent studies of both cases and controls is required to
conﬁrm the involvement of any of these loci with BD.
CNV burden analyses have shown an increased burden of large,
rare CNVs in SZ: we reported a 2.5% higher rate of CNVs larger
than 500 kb in SZ compared with controls.24 Using the same SZ
data set to compare the burden of CNVs in BD revealed a
signiﬁcant difference between SZ and BD with respect to large,
rare CNVs, in particular deletions. However, this excess was
partially explained by the 15 loci already implicated in SZ. When
comparing BD and control samples, we saw no signiﬁcant
difference in CNV burden for any of the CNV sizes examined.
Both observations support our previous ﬁndings examining CNVs
in BD cases and controls genotyped as part of the WTCCC study.16
These ﬁndings do not, however, exclude the involvement of CNVs
in the susceptibility of BD at some speciﬁc loci. However, very
large CNVs appear to contribute less to BD than to SZ.16,32 Larger
structural variants often appear to predispose to persistent, wide-
ranging brain dysfunction, including those that affect cognitive
and personality development.2,23,37
In summary, we have performed CNV analysis in a large
independent BD data set and compared the CNV burden with
both SZ and controls. Our data conﬁrms previous ﬁndings, sug-
gesting that there is a signiﬁcant difference between SZ and BD in
terms of CNV occurrence, in particular for large deletions 41 Mb.
We do not rule out the possibility of CNV involvement in the
susceptibility of BD at speciﬁc loci. In fact, we observe an increase
of duplications at 16p11.2 and 1q21.1, deletions at 3q29 and the
potential involvement of additional CNVs, all of which require
replication.
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